NO313192B1 - Aralkyl og aralkyliden-heterosykliske laktamer og imider, samt farmasöytiske blandinger - Google Patents

Aralkyl og aralkyliden-heterosykliske laktamer og imider, samt farmasöytiske blandinger Download PDF

Info

Publication number
NO313192B1
NO313192B1 NO19991525A NO991525A NO313192B1 NO 313192 B1 NO313192 B1 NO 313192B1 NO 19991525 A NO19991525 A NO 19991525A NO 991525 A NO991525 A NO 991525A NO 313192 B1 NO313192 B1 NO 313192B1
Authority
NO
Norway
Prior art keywords
methylpiperazin
disorder
thiomorpholin
formula
phenyl
Prior art date
Application number
NO19991525A
Other languages
English (en)
Norwegian (no)
Other versions
NO991525L (no
NO991525D0 (no
Inventor
Harry Ralph Howard
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of NO991525D0 publication Critical patent/NO991525D0/no
Publication of NO991525L publication Critical patent/NO991525L/no
Publication of NO313192B1 publication Critical patent/NO313192B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/70—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/96—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
    • C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • C07D265/32—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings with oxygen atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/10—Seven-membered rings having the hetero atoms in positions 1 and 4 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
    • C07D273/02—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00 having two nitrogen atoms and only one oxygen atom
    • C07D273/06—Seven-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/12—1,4-Thiazines; Hydrogenated 1,4-thiazines not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D281/02—Seven-membered rings
    • C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D281/06—Seven-membered rings having the hetero atoms in positions 1 and 4 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
NO19991525A 1996-09-30 1999-03-29 Aralkyl og aralkyliden-heterosykliske laktamer og imider, samt farmasöytiske blandinger NO313192B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2711196P 1996-09-30 1996-09-30
PCT/IB1997/001062 WO1998014433A1 (fr) 1996-09-30 1997-09-08 Lactames et imides heterocycliques d'aralkyle et d'aralkylidene

Publications (3)

Publication Number Publication Date
NO991525D0 NO991525D0 (no) 1999-03-29
NO991525L NO991525L (no) 1999-05-28
NO313192B1 true NO313192B1 (no) 2002-08-26

Family

ID=21835752

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19991525A NO313192B1 (no) 1996-09-30 1999-03-29 Aralkyl og aralkyliden-heterosykliske laktamer og imider, samt farmasöytiske blandinger

Country Status (46)

Country Link
US (6) US6380186B1 (fr)
EP (1) EP0929528B1 (fr)
JP (1) JP3121355B2 (fr)
KR (2) KR100346620B1 (fr)
CN (2) CN1239497C (fr)
AP (1) AP769A (fr)
AR (1) AR008861A1 (fr)
AT (1) ATE245630T1 (fr)
AU (1) AU732451B2 (fr)
BG (1) BG64484B1 (fr)
BR (1) BR9713239A (fr)
CA (1) CA2266107C (fr)
CO (1) CO4650135A1 (fr)
CZ (1) CZ295141B6 (fr)
DE (1) DE69723711T2 (fr)
DK (1) DK0929528T3 (fr)
DZ (1) DZ2321A1 (fr)
EA (1) EA002157B1 (fr)
ES (1) ES2202634T3 (fr)
GT (1) GT199700107A (fr)
HK (1) HK1022313A1 (fr)
HN (1) HN1997000135A (fr)
HR (1) HRP970540B1 (fr)
ID (1) ID19833A (fr)
IL (2) IL140623A (fr)
IS (1) IS4985A (fr)
MA (1) MA26443A1 (fr)
MY (1) MY125749A (fr)
NO (1) NO313192B1 (fr)
NZ (1) NZ334215A (fr)
OA (1) OA11002A (fr)
PA (1) PA8439101A1 (fr)
PE (1) PE2799A1 (fr)
PL (1) PL196005B1 (fr)
PT (1) PT929528E (fr)
RS (1) RS49699B (fr)
SA (2) SA97180449B1 (fr)
SI (1) SI0929528T1 (fr)
SK (1) SK284704B6 (fr)
TN (1) TNSN97161A1 (fr)
TR (1) TR199900660T2 (fr)
TW (1) TW491842B (fr)
UA (1) UA56185C2 (fr)
UY (1) UY24730A1 (fr)
WO (1) WO1998014433A1 (fr)
ZA (1) ZA978703B (fr)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6423708B1 (en) * 1996-09-30 2002-07-23 Pfizer Inc Aralkyl and aralkylidene heterocyclic lactams and imides
UA56185C2 (uk) * 1996-09-30 2003-05-15 Пфайзер Інк. Аралкіл- та аралкіліденгетероциклічні лактами та іміди, фармацевтична композиція та спосіб лікування
DE69919436T2 (de) 1998-04-16 2005-09-15 Pfizer Products Inc., Groton N-Acyl und N-Aroyl Aralkylamide
CA2350597A1 (fr) * 1998-12-02 2000-06-08 Barbara Ann Foster Procedes et compositions pour retablir la stabilite de conformation d'une proteine de la famille p53
ATE277025T1 (de) 1999-03-30 2004-10-15 Pfizer Prod Inc Verfahren zur herstellung von cyclischen thioamiden
DE10022661A1 (de) * 2000-05-10 2001-11-15 Clariant Gmbh Ortho-substituierte Benzaldehyde, Verfahren zu ihrer Herstellung und ihre Verwendung
UA76130C2 (en) 2000-11-20 2006-07-17 Merck Patent Gmbh Use of compounds combining properties of selective inhibitors of serotonin re-uptake and agonists of 5-ht1a receptor for treatment of irritable bowel syndrome
WO2002078643A2 (fr) * 2001-03-30 2002-10-10 Philadelphia Health And Education Corporation Immunomodulation et action sur des processus cellulaires relatifs aux recepteurs de la famille de la serotonine
ES2266416T3 (es) 2001-08-30 2007-03-01 Pfizer Products Inc. Procedimiento para la preparacion de compuestos 2-(4-alquil-1-piperazinil)-benzaldehido y compuestos de -bencilidenilo por sustitucion nucleofila aromatica de 2-fluorobenzaldehido con 4-alquil-1-piperazina en agua como solvente.
EP1746091A1 (fr) * 2001-08-30 2007-01-24 Pfizer Products Inc. Procédure pour la préparation du citrate 2-[-(4-methylpiperazin-1-yl)-benzylidene]-thiomorpholin-3-one 2-substitué
US8575169B2 (en) 2001-10-29 2013-11-05 Versi Group, Llc Method of treating sexual dysfunctions with delta opioid receptor agonist compounds
DK1451166T3 (da) * 2001-12-07 2005-11-14 Pfizer Prod Inc Citronsyresalt af en terapeutisk forbindelse og farmaceutiske kompositioner deraf
US7235573B2 (en) * 2002-09-30 2007-06-26 The Regents Of The University Of California Methods of treating secretory diarrhea using cystic fibrosis transmembrane conductance regulator protein inhibitors
JP4977319B2 (ja) * 2002-09-30 2012-07-18 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 嚢胞性線維症膜コンダクタンス制御因子蛋白質阻害薬およびその使用方法
AU2003282920A1 (en) * 2002-10-04 2004-05-04 Bristol-Myers Squibb Company Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or tnf-alpha converting enzyme (tace)
DE602004028150D1 (de) * 2003-11-26 2010-08-26 Pfizer Prod Inc Aminopyrazolderivate als gsk-3-inhibitoren
WO2005053701A1 (fr) * 2003-11-26 2005-06-16 Pfizer Products Inc. Association d'agonistes de la dopamine et d'imides et lactames heterocycliques d'aralkyle et d'aralkylidene
EP1697353A2 (fr) * 2003-12-15 2006-09-06 Pfizer Products Incorporated Lactames et imides heterocycliques d'aralkyle et d'aralkylidene
US20050171095A1 (en) * 2004-01-06 2005-08-04 Pfizer Inc Combination of CRF antagonists and 5-HT1B receptor antagonists
US20050165025A1 (en) * 2004-01-22 2005-07-28 Recordati Ireland Ltd. Combination therapy with 5HT 1A and 5HT 1B-receptor antagonists
EP1737466A1 (fr) * 2004-01-29 2007-01-03 Pfizer Products Inc. COMBINAISON DE MODULATEURS D'ACIDE GAMMA-AMINOBUTYRIQUE ET D'ANTAGONISTES DU RECEPTEUR 5-HT-1b
EA200601461A1 (ru) * 2004-03-17 2007-02-27 Пфайзер Продактс, Инк. Новые производные бензил(иден)лактама
WO2005105763A1 (fr) 2004-04-30 2005-11-10 Warner-Lambert Company Llc Composes de morpholine substitues permettant de traiter des troubles du systeme nerveux central
EP1753460A2 (fr) * 2004-05-11 2007-02-21 Pfizer Products Inc. Combinaison d'antipsychotiques atypiques et d'antagonistes du recepteur de 5-ht1b
WO2005113526A2 (fr) * 2004-05-21 2005-12-01 Pfizer Products Inc. Metabolites de 4-(3,4-dichloro-phenyl)-2-[2-(4-methyl-piperazin-1-yl)-benzylidene]-thiomorpholin-3-one
EP1753745A2 (fr) * 2004-05-21 2007-02-21 Pfizer Products Inc. Derives pyrazinylmethyle-lactame
WO2006048727A1 (fr) * 2004-11-02 2006-05-11 Pfizer Products Inc. Ligands de latame/amine piperazinylphenalkyle pour le recepteur 5ht1b
WO2006106416A1 (fr) * 2005-04-08 2006-10-12 Pfizer Products Inc. Pyridil-lactams et leur utilisation comme ligands de recepteurs 5-ht1
WO2007026219A2 (fr) * 2005-08-31 2007-03-08 Pfizer Products Inc. Composition d'antagonistes du recepteur 5-ht1b servant au traitement d'etats du systeme nerveux central
WO2007026224A2 (fr) * 2005-08-31 2007-03-08 Pfizer Products Inc. Composition d'antagoniste 5-ht1b pour le traitement de la depression, de l'anxiete et des troubles de la cognition
WO2007057742A2 (fr) * 2005-11-18 2007-05-24 Pfizer Products Inc. Nouveaux derives de piperazinone
GB0701970D0 (en) * 2007-02-01 2007-03-14 Wilson Stuart Treatment of protein aggregation diseases
EP2727915B1 (fr) 2007-09-13 2016-04-13 Concert Pharmaceuticals Inc. Synthèse de catéchols deutériés et benzo[d] [1,3]dioxoles et leurs dérivés
MX2010010343A (es) * 2008-03-25 2010-10-15 Univ California Inhibidores solubles en agua de molecula pequeña del regulador de conductancia transmembrana de fibrosis quistica.
UY31952A (es) 2008-07-02 2010-01-29 Astrazeneca Ab 5-metilideno-1,3-tiazolidina-2,4-dionas sustituidas como inhibidores de quinasa pim
EA029340B1 (ru) * 2011-10-03 2018-03-30 Огеда Са ХИРАЛЬНЫЕ N-АЦИЛ-5,6,7,(8-ЗАМЕЩЕННЫЕ)-ТЕТРАГИДРО[1,2,4]ТРИАЗОЛО[4,3-a]ПИРАЗИНЫ КАК СЕЛЕКТИВНЫЕ АНТАГОНИСТЫ РЕЦЕПТОРА NK-3, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СПОСОБЫ ПРИМЕНЕНИЯ ПРИ НАРУШЕНИЯХ, ОПОСРЕДОВАННЫХ NK-3 РЕЦЕПТОРАМИ, И ИХ ХИРАЛЬНЫЙ СИНТЕЗ
EP3610890A1 (fr) 2012-11-14 2020-02-19 The Johns Hopkins University Procédés et compositions de traitement de la schizophrénie
DE102013019618A1 (de) * 2013-11-25 2015-05-28 Avlen Georges Tri- und Tetracyclische Verbindungen zur Behandlung von Inkontinenz
WO2020183011A1 (fr) 2019-03-14 2020-09-17 Institut Curie Inhibiteurs de htr1d et leurs utilisations dans le traitement du cancer
CN110054597B (zh) * 2019-04-17 2022-11-08 温州大学 一种无金属催化剂条件下合成的噻唑烷-4-酮衍生物及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6229570A (ja) 1985-07-29 1987-02-07 Kanegafuchi Chem Ind Co Ltd ３，５−ジイソプロピルベンジリデン複素環式化合物
HU199134B (en) 1987-12-14 1990-01-29 Richter Gedeon Vegyeszet Process for producing new 2,3-thiomorpholinedine-2-oxime derivatives and pharmaceutical compositions comprising same
IE940525L (en) * 1988-05-25 1989-11-25 Warner Lambert Co Known and selected novel arylmethylenyl derivatives of¹thiazolidinones, imidazolidinones and oxazolidinones useful¹as antiallergy agents and antiinflammatory agents
US5216002A (en) 1989-12-21 1993-06-01 Eli Lilly And Company Method of treating inflammatory bowel disease
DE4119757A1 (de) * 1991-06-15 1992-12-17 Basf Ag Aminoalkylsubstituierte thiazolin-2-one, ihre herstellung und verwendung
CA2099233A1 (fr) * 1992-06-29 1993-12-30 Conrad P. Dorn Antagonistes du recepteur de la tachykinine a base de morpholine et de thiomorpholine
JP2810236B2 (ja) * 1993-03-16 1998-10-15 フアイザー・インコーポレイテツド ナフタレン誘導体
US5556841A (en) 1994-02-04 1996-09-17 Santen Pharmaceutical Co., Ltd. Thiazine or thiomorpholine derivatives
GB9410512D0 (en) * 1994-05-25 1994-07-13 Smithkline Beecham Plc Novel treatment
DK0767782T3 (da) * 1994-06-29 2002-02-18 Pfizer Aryl- og heteroarylalkoxynaphthalenderivater
JP3852787B2 (ja) 1995-06-01 2006-12-06 久光製薬株式会社 チオモルホリン誘導体
EP0779282A1 (fr) * 1995-12-14 1997-06-18 Eli Lilly And Company Dérivés de thiomorpholinone pour le traitement de la sclérose en plaques
UA56185C2 (uk) * 1996-09-30 2003-05-15 Пфайзер Інк. Аралкіл- та аралкіліденгетероциклічні лактами та іміди, фармацевтична композиція та спосіб лікування
US6423708B1 (en) * 1996-09-30 2002-07-23 Pfizer Inc Aralkyl and aralkylidene heterocyclic lactams and imides

Also Published As

Publication number Publication date
AP9701107A0 (en) 1997-10-31
AP769A (en) 1999-09-30
CN1239497C (zh) 2006-02-01
ES2202634T3 (es) 2004-04-01
US20020091118A1 (en) 2002-07-11
NZ334215A (en) 2000-09-29
IL129045A (en) 2005-09-25
KR20000048731A (ko) 2000-07-25
IS4985A (is) 1999-02-26
US6403592B1 (en) 2002-06-11
US6627627B2 (en) 2003-09-30
DZ2321A1 (fr) 2002-12-28
CO4650135A1 (es) 1998-09-03
GT199700107A (es) 1999-03-23
RS49699B (sr) 2007-12-31
EP0929528B1 (fr) 2003-07-23
TR199900660T2 (xx) 1999-07-21
HRP970540B1 (en) 2002-08-31
CN1329002A (zh) 2002-01-02
CZ107199A3 (cs) 2000-05-17
EA002157B1 (ru) 2001-12-24
NO991525L (no) 1999-05-28
PT929528E (pt) 2003-12-31
SA97180449B1 (ar) 2005-12-21
WO1998014433A1 (fr) 1998-04-09
IL140623A (en) 2005-03-20
DK0929528T3 (da) 2003-10-06
UA56185C2 (uk) 2003-05-15
ATE245630T1 (de) 2003-08-15
TW491842B (en) 2002-06-21
SK284704B6 (sk) 2005-09-08
DE69723711T2 (de) 2004-02-05
SI0929528T1 (en) 2003-10-31
PL196005B1 (pl) 2007-11-30
KR100323167B1 (ko) 2002-02-04
UY24730A1 (es) 2000-09-29
ZA978703B (en) 1999-03-30
BG64484B1 (bg) 2005-04-30
SA05260293B1 (ar) 2006-04-18
AU3951497A (en) 1998-04-24
CN1231661A (zh) 1999-10-13
US6921760B2 (en) 2005-07-26
US6562813B2 (en) 2003-05-13
US6472388B2 (en) 2002-10-29
US20020147194A1 (en) 2002-10-10
MY125749A (en) 2006-08-30
OA11002A (en) 2001-11-06
TNSN97161A1 (fr) 2005-03-15
PA8439101A1 (es) 2000-05-24
HK1022313A1 (en) 2000-08-04
JP3121355B2 (ja) 2000-12-25
MA26443A1 (fr) 2004-12-20
US20020072519A1 (en) 2002-06-13
PE2799A1 (es) 1999-02-04
US20020091119A1 (en) 2002-07-11
SA97180449A (ar) 2005-12-03
CA2266107A1 (fr) 1998-04-09
YU16899A (sh) 2002-03-18
PL332629A1 (en) 1999-09-27
SK41099A3 (en) 2000-09-12
JP2000503679A (ja) 2000-03-28
BR9713239A (pt) 2000-04-04
EP0929528A1 (fr) 1999-07-21
BG103297A (en) 1999-11-30
AR008861A1 (es) 2000-02-23
CA2266107C (fr) 2002-12-03
US20020091117A1 (en) 2002-07-11
AU732451B2 (en) 2001-04-26
EA199900242A1 (ru) 1999-08-26
ID19833A (id) 1998-08-06
US6380186B1 (en) 2002-04-30
IL129045A0 (en) 2000-02-17
NO991525D0 (no) 1999-03-29
HN1997000135A (es) 1998-01-28
HRP970540A2 (en) 1998-08-31
KR100346620B1 (ko) 2002-07-26
CZ295141B6 (cs) 2005-05-18
IL140623A0 (en) 2002-02-10
CN1093123C (zh) 2002-10-23
DE69723711D1 (de) 2003-08-28

Similar Documents

Publication Publication Date Title
NO313192B1 (no) Aralkyl og aralkyliden-heterosykliske laktamer og imider, samt farmasöytiske blandinger
US6462048B2 (en) Benzyl(idene)-lactam derivatives, their preparation and their use as selective (ant)agonists of 5-HT1A- and/or 5-HT1D receptors
US6258953B1 (en) Arylacrylamide derivatives
US6423708B1 (en) Aralkyl and aralkylidene heterocyclic lactams and imides
EP1041070B1 (fr) Procédé de préparation de thioamides cycliques
US20050227981A1 (en) Aralkyl and aralkylidene heterocyclic lactam and imides
US20050227980A1 (en) Aralkyl and aralkylidene heterocyclic lactam and imides

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees